<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03140605</url>
  </required_header>
  <id_info>
    <org_study_id>2017-HPLS-IIS</org_study_id>
    <nct_id>NCT03140605</nct_id>
  </id_info>
  <brief_title>Greek Registry - Familial Hypercholesterolaemia</brief_title>
  <acronym>GRegistry-FH</acronym>
  <official_title>Hellenic Registry for Familial Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hellenic College of Treatment of Atherosclerosis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hellenic College of Treatment of Atherosclerosis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Familial hypercholesterolemia (FH) [heterozygous (heFH) or homozygous FH (hoFH)] is a common
      genetic disorder, characterized by elevated plasma low density lipoprotein (LDL) cholesterol
      concentration leading (if untreated) to cholesterol deposits in the corneas, eyelids and
      extensor tendons, rapidly progressing vascular disease, and aortic valve disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In contrast, timely recognition and effective treatment of FH can result in a significant
      improvement in clinical outcomes. The problem is that that majority of individuals with FH
      are unaware of their disease, particularly that the disease remains silent for many years. In
      most countries around the world &lt;5% of individuals with FH are identified .

      Until lately the prevalence of heFH was traditionally considered to be ~ 1:500 individuals ,
      although clinical and genetic studies suggest that heFH affects ~ 1:200-250 individuals .
      Thus, the aim of the Hellenic College of Treatment of Atherosclerosis (HCAT) is to 1).
      Evaluate the prevalence of FH in Greece (FHG-Registry) and 2). To inform population of FH
      disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2017</start_date>
  <completion_date type="Anticipated">January 10, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 10, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Month</target_duration>
  <primary_outcome>
    <measure>the prevalence of Familiar Hypercholesterolaemia in Greece</measure>
    <time_frame>1 month</time_frame>
    <description>patients with FH will be screened and include in Registry</description>
  </primary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Familial Hypercholesterolemia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Sample of citizents on Panhellenic basis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  both genders

          -  &gt;18 years, &lt;80 years

          -  door to door enrolment

          -  eligible to sign informed consent

        Exclusion Criteria:

          -  &lt;18 years, &gt;80 years

          -  deny to sign informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Genovefa Kolovou, MD</last_name>
    <email>genovefa@kolovou.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Onassis Cardiology Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Genovefa Kolovou, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Kolovou GD, Damaskos DS, Anagnostopoulou KK, Salpea KD, Dritsas A, Giannakopoulou V, Vasiliadis IK, Cokkinos DV. Stress testing response in women heterozygous for familial hypercholesterolemia. Int J Cardiol. 2007 Oct 31;122(1):96-7. Epub 2007 Jan 18.</citation>
    <PMID>17239976</PMID>
  </reference>
  <reference>
    <citation>Kolovou GD, Dedoussis GV, Anagnostopoulou KK, Hatzigeorgiou GCh, Salpea KD, Choumerianou DM, Rammos S, Mikhailidis DP, Cokkinos DV. Management of a patient with a null low-density lipoprotein receptor mutation: a case report. Angiology. 2006 Dec-2007 Jan;57(6):729-32.</citation>
    <PMID>17235114</PMID>
  </reference>
  <reference>
    <citation>Kolovou GD, Kostakou PM, Anagnostopoulou KK. Familial hypercholesterolemia and triglyceride metabolism. Int J Cardiol. 2011 Mar 17;147(3):349-58. doi: 10.1016/j.ijcard.2010.08.009. Epub 2010 Sep 9. Review.</citation>
    <PMID>20826022</PMID>
  </reference>
  <reference>
    <citation>Markousis-Mavrogenis G, Mavrogeni S, Kolovou G. Early coronary artery disease--Usual and unusual suspects. Int J Cardiol. 2016 Jan 1;202:511. doi: 10.1016/j.ijcard.2015.09.050. Epub 2015 Sep 25.</citation>
    <PMID>26447655</PMID>
  </reference>
  <reference>
    <citation>Béliard S, Millier A, Carreau V, Carrié A, Moulin P, Fredenrich A, Farnier M, Luc G, Rosenbaum D, Toumi M, Bruckert E; French FH Registry group. The very high cardiovascular risk in heterozygous familial hypercholesterolemia: Analysis of 734 French patients. J Clin Lipidol. 2016 Sep-Oct;10(5):1129-1136.e3. doi: 10.1016/j.jacl.2016.06.007. Epub 2016 Jun 27.</citation>
    <PMID>27678429</PMID>
  </reference>
  <reference>
    <citation>Mundal L, Igland J, Ose L, Holven KB, Veierød MB, Leren TP, Retterstøl K. Cardiovascular disease mortality in patients with genetically verified familial hypercholesterolemia in Norway during 1992-2013. Eur J Prev Cardiol. 2017 Jan;24(2):137-144. doi: 10.1177/2047487316676135. Epub 2016 Oct 28.</citation>
    <PMID>27794106</PMID>
  </reference>
  <reference>
    <citation>EAS Familial Hypercholesterolaemia Studies Collaboration, Vallejo-Vaz AJ, Akram A, Kondapally Seshasai SR, Cole D, Watts GF, Hovingh GK, Kastelein JJ, Mata P, Raal FJ, Santos RD, Soran H, Freiberger T, Abifadel M, Aguilar-Salinas CA, Alnouri F, Alonso R, Al-Rasadi K, Banach M, Bogsrud MP, Bourbon M, Bruckert E, Car J, Ceska R, Corral P, Descamps O, Dieplinger H, Do CT, Durst R, Ezhov MV, Fras Z, Gaita D, Gaspar IM, Genest J, Harada-Shiba M, Jiang L, Kayikcioglu M, Lam CS, Latkovskis G, Laufs U, Liberopoulos E, Lin J, Lin N, Maher V, Majano N, Marais AD, März W, Mirrakhimov E, Miserez AR, Mitchenko O, Nawawi H, Nilsson L, Nordestgaard BG, Paragh G, Petrulioniene Z, Pojskic B, Reiner Ž, Sahebkar A, Santos LE, Schunkert H, Shehab A, Slimane MN, Stoll M, Su TC, Susekov A, Tilney M, Tomlinson B, Tselepis AD, Vohnout B, Widén E, Yamashita S, Catapano AL, Ray KK. Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. Atheroscler Suppl. 2016 Dec;22:1-32. doi: 10.1016/j.atherosclerosissup.2016.10.001. Epub 2016 Dec 7.</citation>
    <PMID>27939304</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2017</study_first_submitted>
  <study_first_submitted_qc>May 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2017</study_first_posted>
  <last_update_submitted>May 15, 2017</last_update_submitted>
  <last_update_submitted_qc>May 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hellenic College of Treatment of Atherosclerosis</investigator_affiliation>
    <investigator_full_name>Genovefa Kolovou, M.D., Ph.D., F.E.S.C., S.F.S.A</investigator_full_name>
    <investigator_title>Cardiologist, Head of Hellenic College of Treatment of Atherosclerosis</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

